Diagnostic performance of transrectal ultrasonography to detect pelvic node metastases evaluated per patient and per site in the whole study population
| Per patient (n=390) | Per site (n=780) | |||
| Results | 95% CI | Results | 95% CI | |
| Detection of pelvic macrometastases only (54 patients) | ||||
| Sensitivity | 72.2% | 60.3% to 84.2% | 72.0% | 61.8% to 82.2% |
| Specificity | 94.0% | 91.5% to 96.6% | 95.9% | 94.4% to 97.4% |
| PPV | 66.1% | 54.0% to 78.2% | 65.1% | 54.8% to 75.3% |
| NPV | 95.5% | 93.2% to 97.7% | 97.0% | 95.7% to 98.3% |
| ACC | 91.0% | 88.2% to 93.9% | 93.6% | 91.9% to 95.3% |
| AUC | 0.831 | 0.758 to 0.904 | 0.839 | 0.778 to 0.901 |
| DOR | 41.1 | 19.5 to 86.8 | 59.9 | 32.0 to 112.1 |
| Detection of pelvic macrometastases and/or micrometastases (pN1, 75 patients) | ||||
| Sensitivity | 53.3% | 42.0% to 64.6% | 52.9% | 43.3% to 62.5% |
| Specificity | 94.0% | 91.3% to 96.6% | 95.9% | 94.4% to 97.4% |
| PPV | 67.8% | 55.9% to 79.7% | 66.3% | 56.1% to 76.4% |
| NPV | 89.4% | 86.1% to 92.7% | 93.0% | 91.1% to 94.9% |
| ACC | 86.2% | 82.7% to 89.6% | 90.1% | 88.0% to 92.2% |
| AUC | 0.737 | 0.663 to 0.810 | 0.744 | 0.682 to 0.805 |
| DOR | 17.8 | 9.3 to 34.1 | 26.0 | 15.1 to 44.6 |
ACC, accuracy; AUC, area under curve; DOR, diagnostic OR ; NPV, negative predictive value; PPV, positive predictive value.